A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer

Molecular Therapy

Volumn 22, Issue 7, 2014, Pages 1254-1265

  Lee, Joong Jae ^a   Kim, Hyun Jung ^b   Yang, Chul Su ^c,e   Kyeong, Hyun Ho ^a   Choi, Jung Min ^a   Hwang, Da Eun ^a   Yuk, Jae Min ^c   Park, Keunwan ^a   Kim, Yu Jung ^d   Lee, Seung Goo ^d   Kim, Dongsup ^a   Jo, Eun Kyeong ^c   Cheong, Hae Kap ^b   Kim, Hak Sung ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

^c Chungnam National University   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^e Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 6; REPEBODY; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; FEMALE; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOLECULAR EVOLUTION; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; NUDE MOUSE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INTERLEUKIN-6; MICE; MICE, NUDE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903763186     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.59     Document Type: Conference Paper

References (54)

1. Kishimoto, T (2005). Interleukin-6: From basic science to medicine-40 years in immunology. Annu Rev Immunol 23: 1-21. (Pubitemid 40563163
2. Simpson, RJ, Hammacher, A, Smith, DK, Matthews, JM and Ward, LD (1997). Interleukin-6: Structure-function relationships. Protein Sci 6: 929-955. (Pubitemid 27194135
3. Hong, DS, Angelo, LS and Kurzrock, R (2007). Interleukin-6 and its receptor in cancer: Implications for translational therapeutics. Cancer 110: 1911-1928. (Pubitemid 350036849
4. Nishimoto, N (2010). Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther 87: 483-487
5. Bromberg, J and Wang, TC (2009). Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15: 79-80
6. Hodge, DR, Hurt, EM and Farrar, WL (2005). The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41: 2502-2512. (Pubitemid 41540626
7. Yu, H, Pardoll, D and Jove, R (2009). STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9: 798-809
8. Yao, Z, Fenoglio, S, Gao, DC, Camiolo, M, Stiles, B, Lindsted, T et al. (2010). TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 107: 15535-15540
9. Gao, SP, Mark, KG, Leslie, K, Pao, W, Motoi, N, Gerald, WL et al. (2007). Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856. (Pubitemid 350224094
10. Siegel, R, Naishadham, D and Jemal, A (2013). Cancer statistics, 2013. CA Cancer J Clin 63: 11-30
11. Herbst, RS, Heymach, JV and Lippman, SM (2008). Lung cancer. N Engl J Med 359: 1367-1380
12. Ramalingam, SS, Owonikoko, TK and Khuri, FR (2011). Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin 61: 91-112
13. Cortas, T, Eisenberg, R, Fu, P, Kern, J, Patrick, L and Dowlati, A (2007). Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer 55: 349-355. (Pubitemid 46343578
14. Haura, EB, Livingston, S and Coppola, D (2006). Autocrine interleukin-6/ interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin Lung Cancer 7: 273-275. (Pubitemid 43280031
15. McInnes, IB and Schett, G (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7: 429-442. (Pubitemid 46834849
16. Reichert, JM (2013). Which are the antibodies to watch in 2013? MAbs 5: 1-4
17. Scott, AM, Wolchok, JD and Old, LJ (2012). Antibody therapy of cancer. Nat Rev Cancer 12: 278-287
18. Chames, P, Van Regenmortel, M, Weiss, E and Baty, D (2009). Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol 157: 220-233
19. Binz, HK, Amstutz, P and Pluckthun, A (2005). Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23: 1257-1268. (Pubitemid 41486853
20. Xu, G, Tasumi, S and Pancer, Z (2011). Yeast surface display of lamprey variable lymphocyte receptors. Methods Mol Biol 748: 21-33
21. Wezner-Ptasinska, M, Krowarsch, D and Otlewski, J (2011). Design and characteristics of a stable protein scaffold for specific binding based on variable lymphocyte receptor sequences. Biochim Biophys Acta 1814: 1140-1145
22. Boersma, YL and Pluckthun, A (2011). DARPins and other repeat protein scaffolds: Advances in engineering and applications. Curr Opin Biotechnol 22: 849-857
23. Lee, SC, Park, K, Han, J, Lee, JJ, Kim, HJ, Hong, S et al. (2012). Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering. Proc Natl Acad Sci USA 109: 3299-3304
24. Boehm, T, McCurley, N, Sutoh, Y, Schorpp, M, Kasahara, M and Cooper, MD (2012). VLR-based adaptive immunity. Annu Rev Immunol 30: 203-220
25. Deng, L, Luo, M, Velikovsky, A and Mariuzza, RA (2013). Structural insights into the evolution of the adaptive immune system. Annu Rev Biophys 42: 191-215
26. Boulanger, MJ, Chow, DC, Brevnova, EE and Garcia, KC (2003). Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300: 2101-2104. (Pubitemid 36760138
27. Fulciniti, M, Hideshima, T, Vermot-Desroches, C, Pozzi, S, Nanjappa, P, Shen, Z et al. (2009). A high-Affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 15: 7144-7152
28. Trikha, M, Corringham, R, Klein, B and Rossi, JF (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665. (Pubitemid 37323267
29. Kalai, M, Montero-Julian, FA, Brakenhoff, JP, Fontaine, V, De Wit, L, Wollmer, A et al. (1997). Analysis of the mechanism of action of anti-human interleukin-6 and antihuman interleukin-6 receptor-neutralising monoclonal antibodies. Eur J Biochem 249: 690-700. (Pubitemid 27479039
30. Selzer, T, Albeck, S and Schreiber, G (2000). Rational design of faster associating and tighter binding protein complexes. Nat Struct Biol 7: 537-541. (Pubitemid 30445907
31. Heinrich, PC, Behrmann, I, Haan, S, Hermanns, HM, Muller-Newen, G and Schaper, F (2003). Principles of interleukin (IL)-6-Type cytokine signalling and its regulation. Biochem J 374(Pt 1): 1-20. (Pubitemid 37046923
32. De Groot, AS and Scott, DW (2007). Immunogenicity of protein therapeutics. Trends Immunol 28: 482-490. (Pubitemid 350087812
33. Guo, Y, Xu, F, Lu, T, Duan, Z and Zhang, Z (2012). Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38: 904-910
34. Scambia, G, Testa, U, Benedetti Panici, P, Foti, E, Martucci, R, Gadducci, A et al. (1995). Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71: 354-356
35. Gabay, C, Emery, P, van Vollenhoven, R, Dikranian, A, Alten, R, Pavelka, K et al.; ADACTA Study Investigators. (2013). Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, doubleblind, controlled phase 4 trial. Lancet 381: 1541-1550
36. Nguyen, MN, Tan, KP and Madhusudhan, MS (2011). CLICK-Topology- independent comparison of biomolecular 3D structures. Nucleic Acids Res 39(Web Server issue): W24-W28
37. Tuncbag, N, Keskin, O and Gursoy, A (2010). HotPoint: Hot spot prediction server for protein interfaces. Nucleic Acids Res 38(Web Server issue): W402-W406
38. Rudnick, SI, Lou, J, Shaller, CC, Tang, Y, Klein-Szanto, AJ, Weiner, LM et al. (2011). Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 71: 2250-2259
39. Adams, GP, Schier, R, Marshall, K, Wolf, EJ, McCall, AM, Marks, JD et al. (1998). Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58: 485-490. (Pubitemid 28087411
40. Weinstein, JN, Eger, RR, Covell, DG, Black, CD, Mulshine, J, Carrasquillo, JA et al. (1987). The pharmacology of monoclonal antibodies. Ann N Y Acad Sci 507: 199-210
41. Grivennikov, S and Karin, M (2008). Autocrine IL-6 signaling: A key event in tumorigenesis? Cancer Cell 13: 7-9. (Pubitemid 350309747
42. Grivennikov, S, Karin, E, Terzic, J, Mucida, D, Yu, GY, Vallabhapurapu, S et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-Associated cancer. Cancer Cell 15: 103-113
43. Williams, SC (2013). First IL-6-blocking drug nears approval for rare blood disorder. Nat Med 19: 1193
44. Lu, ZY, Brochier, J, Wijdenes, J, Brailly, H, Bataille, R and Klein, B (1992). High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 22: 2819-2824
45. Martens, E, Dillen, C, Put, W, Heremans, H, van Damme, J and Billiau, A (1993). Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-Antibody complexes. Eur J Immunol 23: 2026-2029. (Pubitemid 23236805
46. The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrodinger, LLC. www. pymol.org/citing
47. Song, L, Rawal, B, Nemeth, JA and Haura, EB (2011). JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 10: 481-494
48. Lee, CM, Iorno, N, Sierro, F and Christ, D (2007). Selection of human antibody fragments by phage display. Nat Protoc 2: 3001-3008
49. Bent WS (2000). Exact analysis of competition ligand binding by displacement isothermal titration calorimetry. Anal Biochem 277: 260-266
50. Velazquez-Campoy, A and Freire, E (2006). Isothermal titration calorimetry to determine association constants for high-Affinity ligands. Nat Protoc 1: 186-191
51. Hess B, Kutzner C, van der Spoel D, Lindahl E. (2008). GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4:435-447
52. Schuler LD, Daura X, van Gunsteren WF. (2001). An improved GROMOS96 force field for aliphatic hydrocarbons in the condensed phase. J Comput Chem 22:1205-1218. (Pubitemid 32662797
53. Darden T, York D, Pedersen L. (1993). Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems. J Chem Phys 98:10089-10092
54. Yang, CS, Lee, JS, Lee, HM, Shim, TS, Son, JW, Jung, SS et al. (2008). Differential cytokine levels and immunoreactivities against Mycobacterium tuberculosis antigens between tuberculous and malignant effusions. Respir Med 102: 280-286.